ABL1 and acute lymphoblastic leukemia: An observation made by Weston et al. indicated that BCR-ABL1-like ALL patients with EBF1-PDGFRB rearrangements (identified in 8% of patients) could be successfully treated with TKI in cases refractory to conventional four-drug induction therapy [79,80].